Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
Career Development Program FAQ
News
LLS Applauds Data from Celator Study of CPX-351 for High-Risk AML Patients
White Plains, N.Y. (June 24, 2015) – Interim data released today by Celator Pharmaceuticals regarding its study of CPX-351, a special formulation of …
Who We Are
Surviving AML: The Long Road Back
Media resources
Email
Contact us for inquiries and interview requests.
Press Kit
Explore details for journalists and media outlets.
Brand Center
Access approved logos, guidelines, and other assets.